IKS014 i avanserte solide svulster som uttrykker HER2
En fase 1-doseeskaleringsforsøk for å bestemme sikkerhet, toleranse, maksimal tolerert dose og foreløpig antineoplastisk aktivitet til IKS014, et HER2-målrettet antistoffmedikamentkonjugat (ADC), hos deltakere med avanserte HER2+ solide svulster
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). The dose-escalation part (Part 1) of the study is to evaluate the safety and tolerability of increasing dose levels of IKS014 to establish a recommended phase 2 dose (RP2D); and the dose-expansion part (Part 2) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of IKS014 at the RP2D.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: David Browning
- Telefonnummer: +1-615-975-7776
- E-post: david.browning@iksuda.com
Studiesteder
-
-
New South Wales
-
Concord, New South Wales, Australia, 2139
- Rekruttering
- Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit
-
Hovedetterforsker:
- Tam Bui, MD
-
Sydney, New South Wales, Australia, 2109
- Rekruttering
- Macquarie University
-
Hovedetterforsker:
- Dhanusha Sabanathan, MD
-
Westmead, New South Wales, Australia, 2145
- Rekruttering
- Westmead Hospital
-
Hovedetterforsker:
- Adnan Nagrial, MD
-
-
Victoria
-
Frankston, Victoria, Australia, 3199
- Rekruttering
- Peninsula & South Eastern Haematology and Oncology Group (PSEHOG)
-
Hovedetterforsker:
- Vinod Ganju, MD
-
Melbourne, Victoria, Australia, 3004
- Rekruttering
- Alfred Health
-
Hovedetterforsker:
- Malaka Ameratunga, MD
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Rekruttering
- Linear Clinical Research
-
Hovedetterforsker:
- Peter Lau, MD
-
-
-
-
California
-
Newport Beach, California, Forente stater, 92663
- Rekruttering
- Hoag Memorial Hospital Presbyterian
-
Hovedetterforsker:
- Monica Mita, MD
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Dana Farber Cancer Institute
-
Hovedetterforsker:
- Nancy Lin, MD
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tennessee Oncology
-
Hovedetterforsker:
- Jeffrey Russell, MD
-
-
Texas
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- START Dallas - Fort Worth
-
Hovedetterforsker:
- Henry Xiong, MD
-
Ta kontakt med:
- Hope Team
- E-post: hopeteam@startresearch.com
-
-
-
-
-
Auckland, New Zealand
- Rekruttering
- Auckland City Hospital
-
Hovedetterforsker:
- Jane So, MBChB
-
-
-
-
-
Singapore, Singapore
- Rekruttering
- National Cancer Centre Singapore
-
Hovedetterforsker:
- Jing Ying Tira Tan, MBBS
-
Singapore, Singapore
- Rekruttering
- Tan Tock Seng Hospital
-
Hovedetterforsker:
- Yue Ming Valerie Heong, MBBS
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
HER2 positive solid tumors with expression defined as IHC3+, IHC2+/ISH+, or low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH- /+ or untested).
-
Participants with HR positive BC must have received prior treatment with a CDK4/6 inhibitor, in countries where this is standard therapy.
-
Platelets ≥ 75,000 /mcL
-
Hemoglobin ≥ 9.0 g/dL
-
Absolute neutrophil count ≥ 1000/mcL
-
No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 2 weeks prior to first study drug administration
-
Creatinine clearance > 45/mL/min (using the Cockcroft-Gault equation)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x institutional upper limit of normal (ULN) ≤ 5 x ULN if liver metastases present
-
Total bilirubin ≤ 1.5 x ULN if no liver metastases or < 3 x ULN with Gilbert's Syndrome or liver metastases at baseline
-
Albumin > 2.5 g/dL
-
Prothrombin time or international normalized ratio (INR) and either partial thromboplastin time (PTT) or activated (a) PTT ≤ 1.5 x ULN, ≤ 3 x institutional ULN if anticoagulated.
-
Must have adequate treatment washout period before trial treatment, defined as: Major surgery (≥ 4 weeks) and radiation therapy (≥ 3 weeks; in case of palliative radiation ≥ 2 weeks)
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (or equivalent Karnofsky PS)
-
Part 2 Dose Expansion Cohorts May Include:
- Advanced or metastatic BC that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH, as per ASCO-CAP and previously treated with at least two HER2 directed treatments.
- Advanced or metastatic BC that has low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH-/+ or untested) and previously treated with at least 1 prior line of therapy which may include chemotherapy and/or a HER2 directed ADC.
- Advanced or metastatic GC or GEJ cancer that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH as per ASCO-CAP and previously treated with at least 1 prior line of therapy, which may include chemotherapy and/or a HER2 directed ADC.
- Advanced or metastatic solid tumor that has been treated with standard of care therapy and is HER2 positive (HER2 IHC3+) as per ASCO-CAP or metastatic NSCLC (that has been treated with standard of care therapy) with a known activating HER2 (ERBB2) mutation.
- Advanced or metastatic adenocarcinoma of the Esophagus that has been treated with at least one prior line of standard treatment, which may have included a HER2-directed therapy. The tumor must be HER2 positive defined either HER2 IHC3+ or HER2 IHC 2+/ISH+.
Key Exclusion Criteria:
-
History of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
-
Any clinically apparent ≥ Grade 2 pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the trial enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis), or prior pneumonectomy.
-
Current evidence of ≥ Grade 2 keratitis or other corneal abnormality.
-
Evidence of a clinically significant (≥ Grade 2) abnormality on slit-lamp examination or other clinically significant ophthalmologic finding, as determined by an ophthalmologist.
-
Evidence of clinically significant (≥ Grade 2) confluent superficial keratitis, a corneal epithelial defect, a corneal ulcer, or stromal opacity.
-
Participant must not use contact lenses while participating in this study.
-
Central nervous system metastatic disease unless treated with definitive local therapy (surgical resection, stereotactic radiotherapy, or whole brain radiotherapy) and participant is clinically, radiologically and neurologically stable for at least 4 weeks prior to the first dose of study drug not on steroid therapy or are on a stable or decreasing dose of steroids for at least 7 days prior to first dose of study drug. Prophylactic anticonvulsant medications are allowed.
-
Active second malignancy or history of another malignancy within the last 2 years with the exception of:
- Treated, non-melanoma skin cancers
- Treated carcinoma in situ (CIS) (e.g., breast, cervix)
- Controlled, superficial carcinoma of the urinary bladder
- T1a or b carcinoma of the prostate treated according to local standard of care, with prostate specific antigen (PSA) within normal limits (WNL) for the institution
- Papillary thyroid carcinoma Stage I treated surgically for cure
-
Clinically significant cardiovascular disease or condition
-
Clinically significant liver disease
-
Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks prior to first trial drug administration.
-
Any other serious, life-threatening, or unstable preexisting medical condition (aside from the underlying malignancy), including significant organ system dysfunction, or clinically significant laboratory abnormality(ies), which, in the opinion of the Investigator, would either compromise the participant's safety or interfere with obtaining informed consent, compliance with trial procedures, or evaluation of the safety of the trial drug.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose Escalation Cohort (Part 1)
Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Eksperimentell: Dose Expansion: HER2+ Breast Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Eksperimentell: Dose Expansion: HER2 Low Breast Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Eksperimentell: Dose Expansion: HER2+ Gastric Cancer or Gastro-esophageal Junction Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Eksperimentell: Dose Expansion: HER2 Low Gastric Cancer or Gastro-esophageal Junction Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
Eksperimentell: Dose Expansion: HER2 Solid Tumor Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Recommended Phase 2 Dose (Part 1)
Tidsramme: Up to 24 months
|
Based on tolerability, preliminary anti-tumor activity, and pharmacokinetics |
Up to 24 months
|
|
Objective Response Rate (Part 2)
Tidsramme: Up to 24 months
|
Anti-tumor activity will be assessed by RECIST 1.1 |
Up to 24 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (Part 1)
Tidsramme: Up to 24 months
|
Anti-tumor activity will be assessed by RECIST 1.1 |
Up to 24 months
|
|
Plasma Concentrations of IKS014 (Part 1 and 2)
Tidsramme: Up to 48 months
|
Pharmacokinetic parameters will be determined from observed concentrations of IKS014 |
Up to 48 months
|
|
Evaluation of the immunogenicity of IKS014 (Part 1 and 2)
Tidsramme: Up to 48 months
|
Occurrence of ADA measured in serum at selected timepoints during the study |
Up to 48 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: James O'Leary, MD, Iksuda Therapeutics
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IKS014-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .